Last update 21 Nov 2024

Periciazine

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile, 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine, 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine

+ [10]

Target

DRDs

Mechanism

DRDs antagonists(Dopamine receptors antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Schizophrenia

Inactive Indication-

Originator Organization

Takada Corp.

Active Organization

Takada Corp.Takata Seiyaku Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (07 Apr 1964),

Schizophrenia

Regulation-

Structure

Molecular FormulaC21H23N3OS

InChIKeyLUALIOATIOESLM-UHFFFAOYSA-N

CAS Registry2622-26-6

Clinical Trials associated with Periciazine

ChiCTR-IIR-16008062 / RecruitingPhase 1IIT

Bioequivalence of Pericyazine Tablets (Fasting ) in the Human Body

Start Date12 Mar 2016

Sponsor / Collaborator-

100 Clinical Results associated with Periciazine

100 Translational Medicine associated with Periciazine

100 Patents (Medical) associated with Periciazine

166

Literatures (Medical) associated with Periciazine

15 Jun 2024·Internal Medicine

Polypharmacy-related Shock Symptoms and Complications Associated with Phenothiazine

Article

Author: Oda, Shinya ; Yamakawa, Daisuke ; Ishima, Tamaki ; Aizawa, Kenichi ; Nakamura, Shunsuke ; Kimura, Natsuka ; Yamaguchi, Shota ; Masuda, Shingo

This report describes a case of shock symptoms in a 72-year-old woman with epilepsy who had been in a state of polypharmacy, taking multiple antipsychotic drugs. After receiving a normal dose of periciazine, she exhibited impaired consciousness, hypothermia, and hypotension and was admitted to hospital. Despite poor response to vasopressors, conservative treatment led to gradual improvement. Subsequent pharmacokinetic analysis showed non-toxic blood concentrations of periciazine, suggesting that even small doses of phenothiazines could result in toxic symptoms. This case highlights the importance of monitoring for adverse reactions when prescribing multiple antipsychotic drugs, particularly in older polypharmacy patients.

01 Dec 2022·Journal of Pharmaceutical Health Care and Sciences

Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: a case report

Article

Author: Yakuwa, Naho ; Saito, Jumpei ; Kawasaki, Hiroyo ; Tachibana, Yoshiyuki ; Wada, Yuka Sano ; Suzuki, Tomo ; Sago, Haruhiko ; Yamatani, Akimasa ; Murashima, Atsuko

AbstractBackgroundA high prevalence of mental disorders including depression, anxiety, somatoform, and dissociative disorder is reported during pregnancy, however, information on the transfer of antipsychotics across the placenta and into breast milk is limited. We evaluated brotizolam, periciazine and sulpiride in cord blood, maternal serum, and breast milk, and alprazolam in breast milk.Case presentationA 38-year-old woman with dissociative disorder was treated with brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and alprazolam during lactation. The drug concentration ratios for both cord blood and maternal serum were 33.3 and 61.5% for brotizolam and sulpiride, respectively, and periciazine (metabolite of propericiazine) was not detected in the cord blood. In breast milk, alprazolam (0.9 ng/mL), sulpiride (445.8 ng/mL), and periciazine (0.3 ng/mL) concentrations were noted at 7.5 h after the last dose on postpartum, whereas brotizolam was not detected. The relative infant doses via breast milk were 1.4, 2.7 and 0.02% of the maternal daily dose, respectively. The neonate had no congenital anomalies and did not experience any severe withdrawal symptoms after birth.ConclusionUse of brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and use of alprazolam during lactation were acceptable in this case.

01 Jan 2020·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease

Article

Author: Khannanova, A N ; Sozarukova, M M ; Sokolova, S V ; Grishina, N K ; Portnova, G V ; Proskurnina, E V

OBJECTIVETo study the antioxidant profile of blood plasma in patients with paranoid schizophrenia and Alzheimer disease (AD).MATERIAL AND METHODSThirty-three patients with paranoid schizophrenia and 18 patients with AD were included in the study. Patients with schizophrenia were stratified into two subgroups by response to therapy. The indicators of the antioxidant profile were determined using methods based on chemiluminometry and spectrofluorimetry.RESULTSSystemic oxidative stress due to insufficiency of low molecular weight plasma antioxidants is not determined neither in AD nor in treatment resistant schizophrenia. At the same time, a «thiol» oxidative stress, which indirectly indicates a deficiency of the glutathione system, is present in both groups. In patients with paranoid schizophrenia responsive to treatment, systemic oxidative stress is more pronounced and «thiol» oxidative stress is less significant. Among the antipsychotics studied, haloperidol, zuclopenthixol, risperidone and ziprasidone do not exhibit antioxidant properties, but periciazine, clozapine and especially chlorpromazine exhibit strong antioxidant properties, but they unlikely affect the antioxidant potential of blood plasma.CONCLUSIONSThe glutathione part of the antioxidant system is mostly affected, but systemic oxidative stress is not significant in patients with treatment resistant paranoid schizophrenia and AD. Oxidative disorders are more pronounced in treatment responsive paranoid schizophrenia.

100 Deals associated with Periciazine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Periciazine	N05AC01	DB01608

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	JP	Takata Seiyaku Co., Ltd.	07 Apr 1964
Schizophrenia	JP	Takada Corp.	07 Apr 1964

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis